PTPRC and mantle cell lymphoma: As shown in Figure S2 all mice co-injected with MCL and hMSC became moribund between 100–150 days and had significant (p = 0.001) engraftment of human CD45 cells in the spleen (Figure S3) compared to mice injected with MCL cells alone or co-injected with MS-5 cells.